KalVista meets main goals in late-stage trial for genetic disease (updated)

Kalvista Pharmaceuticals

13/02/2024 12:10

(Adds details from paragraphs 2 to 4)
       Feb 13 (Reuters) - KalVista Pharmaceuticals  KALV.O 
said on Tuesday its therapy for a type of genetic condition,
which causes rapid swelling under the skin and in other parts of
the body, met main goals in a late-stage trial.
    The therapy, sebetralstat, showed beginning of symptom
relief in patients with hereditary angioedema (HAE)
significantly faster than placebo.
    The median time to beginning of symptom relief was 1.61
hours with the lower dose version of sebetralstat and 6.72 hours
with placebo.
    Sebetralstat was tested in 136 adult and adolescent patients
with HAE — a disease caused by the lack or dysfunction of a
certain protein called C1-inhibitor. 

 (Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
 ((Christy.Santhosh@thomsonreuters.com;))